The development of evidence-based guidelines for over-the-counter treatment of vulvovaginal candidiasis

Pharmacy World and Science

Volumn 25, Issue 4, 2003, Pages 177-181

  Bond, Christine M ^a   Watson, Margaret C ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Community pharmacy; Evidence based practice; Guidelines; United Kingdom; Vulvovaginal candidiasis

Indexed keywords

ANTIFUNGAL AGENT; NON PRESCRIPTION DRUG;

ALGORITHM; ARTICLE; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; PHARMACY; PRACTICE GUIDELINE; PREDICTION; SYMPTOM; VAGINA CANDIDIASIS;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; CANDIDIASIS, VULVOVAGINAL; CLINICAL TRIALS; COMMUNITY PHARMACY SERVICES; DRUGS, NON-PRESCRIPTION; EVIDENCE-BASED MEDICINE; FEMALE; GREAT BRITAIN; HUMANS;

EID: 0042663813     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024842712675     Document Type: Article

References (27)

1. Department of Health. Pharmacy in the future - Implementing the NHS plan. A programme for pharmacy in the National Health Service. London: Department of Health, 2000.
2. Scottish Executive. The right medicine. A strategy for pharmaceutical care in Scotland. Edinburgh: HMSO, 2002.
3. Sobel J, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy P et al. Vulvovaginal candidiasis: epidemiologic, diagnostic and therapeutic considerations. Am J Obstet Gynecol 1998; 178: 203-11.
4. Nyirjesy P, Weitz M, Grody M, Lorber B. Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms. Obstet Gynecol Surv 1997; 90: 50-3.
5. Sihvo S, Ahonen R, Mikander H, Hemminki E. Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization patterns. Fam Pract 2000; 17: 145-9.
6. Matheson C, Bond CM, Flett G, Kennedy E, Duthie I. Over the counter emergency contraception: a feasible option. Fam Pract 1998; 15: 38-43.
7. Porteous T, Bond CM, Duthie I, Matheson C. Guidelines for the treatment of self limiting upper respiratory tract ailments. Pharm J 1998; 260: 134-9.
8. Porteous T, Bond CM, Düthie I, Matheson C. Guidelines for the treatment of hayfever and other allergic conditions of the upper respiratory tract. Pharm J 1997; 259: 62-5.
9. Bond CM. Lower gastrointestinal symptoms. Pharm J 1995; 253: 656-8.
10. Bond CM, Grimshaw J, Taylor RJ, Winfield A. An evaluation of clinical guidelines for community pharmacy. J Soc Admin Pharm 1998; 15: 33-9.
11. Bond CM, Grimshaw J. Multidisciplinary guideline development: a case study from community pharmacy. Health Bull 1995; 53: 26-33.
12. Gallagher M, Hares T, Spencer J, Bradshaw C, Webb I. The nominal group technique: a research tool for general practice? Fam Pract 1993; 10: 76-81.
13. Watson MC, Bond CM, Grimshaw JM, Mollison J, Ludbrook A, Walker A. Educational strategies to promote evidence-based community pharmacy practice: a cluster randomised controlled trial (RCT). Fam Pract 2002; 19: 529-36.
14. Leape LL, Freshour MA, Yntema D, Hsiao W. Small-group judgement methods for determining resource-based relative values. Med Care 1992; 30: ns28-ns39.
15. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. BJOG 2002; 109: 85-95.
16. Watson MC, Grimsha JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of acute, uncomplicated vulvovaginal candidiasis (thrush) (Cochrane Review). The Cochrane Library 2, 2001.
17. Geiger AM, Foxman B, Sobel JD. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitour Med 1995; 71: 304-7.
18. Eckert LO, Hawes SE, Stevens C, Koutsky LA, Eschenbach DA, Holmes KK. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 1998; 92: 757-65.
19. McCormack WM, Starko KM, Zinner S. Symptoms associated with vaginal colonization with yeast. Am J Obstet Gynecol 1988; 158: 31-3.
20. Mårdh P, Tchoudomirova K, Elshibly S, Hellberg D. Symptoms and signs in single and mixed genital infections. Int J Gynaecol Obstet 1998; 63: 145-52.
21. Eschenbach DA, Hillier SL, Critchlow C, Stevens C, DeRouen T, Holmes K. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988; 158: 819-28.
22. Bisschop MPJM, Merkus J, Scheygrond H, Van Cutsem J. Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study. BJOG 1986; 93: 79-81.
23. Centers for Disease Control and Prevention. 1998 Guidelines for treatment of sexually transmitted disease. MMWR Morb Mortal Weekly Report 47(RR-1), 6-10, 1998.
24. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). National guideline on the management of vulvovaginal candidiasis. Sex Transm Infect 1999; 75: S19-S20.
25. Fong IW. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitour Med 1992; 68: 174-6.
26. O'Dowd T, Parker S, Kelly A. Women's experience of general practitioner management of their vaginal symptoms. BJGP 1996; 46: 415-8.
27. Chaponis R, Bresnick P, Weiss R, Edwards L. Candida vaginitis: Signs and symptoms aid women's self-recognition. J Clin Res Drug Dev 1993; 7: 17-23.